Enovis Co. (NYSE:ENOV) Shares Sold by Quent Capital LLC

Quent Capital LLC reduced its position in Enovis Co. (NYSE:ENOV) by 32.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 968 shares of the company’s stock after selling 474 shares during the quarter. Quent Capital LLC’s holdings in Enovis were worth $42,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Stephens Inc. AR purchased a new stake in shares of Enovis during the 4th quarter worth $3,740,000. Entropy Technologies LP boosted its position in shares of Enovis by 8.9% during the 4th quarter. Entropy Technologies LP now owns 7,305 shares of the company’s stock worth $321,000 after purchasing an additional 598 shares in the last quarter. Empowered Funds LLC purchased a new stake in shares of Enovis during the 4th quarter worth $253,000. Leisure Capital Management purchased a new stake in shares of Enovis during the 4th quarter worth $984,000. Finally, DAVENPORT & Co LLC boosted its position in shares of Enovis by 6.0% during the 4th quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company’s stock worth $121,181,000 after purchasing an additional 157,216 shares in the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis Price Performance

Enovis stock opened at $43.70 on Friday. Enovis Co. has a 52 week low of $38.27 and a 52 week high of $65.03. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The firm’s 50-day simple moving average is $45.53 and its 200 day simple moving average is $44.43. The firm has a market capitalization of $2.48 billion, a PE ratio of -19.96 and a beta of 1.94.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC restated a “buy” rating and set a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.83.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.